PF-05089771

PF-05089771 is an experimental drug developed by Pfizer for the treatment of neuropathic pain. It is a selective Nav1.7 inhibitor, which means it works by blocking the Nav1.7 sodium channel that is often associated with the transmission of pain signals in the body.

History

PF-05089771 was first synthesized by Pfizer in the early 2010s as part of their research into novel treatments for neuropathic pain. The drug was designed to target the Nav1.7 sodium channel, which had been identified as a key player in the transmission of pain signals.

Mechanism of Action

PF-05089771 works by selectively inhibiting the Nav1.7 sodium channel. This channel is found in neurons and is involved in the transmission of pain signals. By blocking this channel, PF-05089771 can potentially reduce the perception of pain.

Clinical Trials

PF-05089771 has undergone several phases of clinical trials. Initial trials showed promise, with the drug demonstrating a significant reduction in pain scores compared to a placebo. However, further trials are needed to confirm these results and to further investigate the drug's safety and efficacy.

Potential Applications

If approved, PF-05089771 could be used to treat a variety of conditions associated with neuropathic pain, including diabetic neuropathy, postherpetic neuralgia, and certain types of cancer pain.

See Also

• Pfizer
• Neuropathic pain
• Nav1.7
• Clinical trial

This article is a stub related to pharmacology. You can help WikiMD by expanding it!